# US 2026/0076977 A1 · Methods for treatment of diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0076977 A1
- Document ID: US20260076977A1
- Status: Published application
- Kind: A1
- Application number: 19/334,255
- Filed: 2025-09-19
- Published: 2026-03-19
- Earliest claimed: 2011-09-26
- Applicants: Galera Labs, LLC
- Inventors: Jeffery L. KEENE; Dennis P. RILEY; Robert A. BEARDSLEY
- Web page: https://patentgrep.com/patent/US20260076977A1

## CPC

- A61K 31/555: containing heavy metals, e.g. hemin, hematin, melarsoprol
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 7/06: Antianaemics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/02: Nasal agents, e.g. decongestants
- A61P 11/06: Antiasthmatics
- A61P 13/12: of the kidneys
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/06: Antipsoriatics
- A61P 17/10: Anti-acne agents
- A61P 17/12: Keratolytics, e.g. wart or anti-corn preparations
- A61P 17/14: for baldness or alopecia
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 19/10: for osteoporosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 39/00: General protective or antinoxious agents
- A61P 39/06: Free radical scavengers or antioxidants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure relates to methods of treating a range of diseases or conditions. The methods involve administration of a superoxide dismutase mimetic.

## Claims

### Claim at position 1

1: A unit dose formulation comprising at least 50 mg of a superoxide dismutase mimetic in a container, the superoxide dismutase mimetic corresponding to Formula (GC4419):
wherein X and Y are independently neutral or negatively-charged ligands.

### Claim at position 2 (depends on 1)

2: The unit dose formulation of claim 1, which comprises at least 600 mg of the superoxide dismutase mimetic.

### Claim at position 3 (depends on 1)

3: The unit dose formulation of claim 1, wherein the superoxide dismutase mimetic is in the form of a lyophilized powder.

### Claim at position 4 (depends on 1)

4: The unit dose formulation of claim 1, wherein the container further includes a pharmaceutically acceptable carrier.

### Claim at position 5 (depends on 4)

5: The unit dose formulation of claim 4, wherein the pharmaceutically acceptable carrier comprises a buffered saline solution.

### Claim at position 6 (depends on 4)

6: The unit dose formulation of claim 4, wherein the pharmaceutically acceptable carrier comprises a bicarbonate-buffered saline solution.

### Claim at position 7 (depends on 1)

7: The unit dose formulation of claim 1, wherein X and Y are independently selected from monodentate ligands.

### Claim at position 8 (depends on 1)

8: The unit dose formulation of claim 1, wherein X and Y are independently selected from the group consisting of aquo ligands, halo ligands, carboxylato ligands, and bicarbonato ligands.

### Claim at position 9 (depends on 8)

9: The unit dose formulation of claim 8, wherein X and Y are chloro ligands.

### Claim at position 10 (depends on 1)

10: The unit dose formulation of claim 1, wherein the formulation is stored in a container for storage or for administration to a patient.

### Claim at position 11 (depends on 10)

11: The unit dose formulation of claim 10, wherein the container is a vial, a syringe, or an IV bag or bottle.

### Claim at position 12

12: A method of treating a disease or condition in a human patient, the method comprising administering to the patient at least 25 mg of a superoxide dismutase mimetic at a rate of at least 100 mg/hr, wherein the superoxide dismutase mimetic corresponds to Formula (GC4419):
and X and Y are independently neutral or negatively-charged ligands.

### Claim at position 13 (depends on 12)

13: The method of claim 12, wherein the superoxide dismutase mimetic is administered at a rate of at least 600 mg/hr.

### Claim at position 14 (depends on 12)

14: The method of claim 12, wherein at least 50 mg of the superoxide dismutase mimetic is administered to the patient.

### Claim at position 15 (depends on 12)

15: The method of claim 12, wherein at least 600 mg of the superoxide dismutase mimetic is administered to the patient.

### Claim at position 16 (depends on 12)

16: The method of claim 12, wherein the administration occurs within a 15 minute time period.

### Claim at position 17 (depends on 12)

17: The method of claim 12, wherein the administration occurs within a 60 minute time period.

### Claim at position 18 (depends on 12)

18: The method of claim 12, wherein the superoxide dismutase mimetic is administered parenterally.

### Claim at position 19 (depends on 12)

19: The method of claim 12, wherein the superoxide dismutase mimetic is administered intravenously.

### Claim at position 20 (depends on 12)

20: The method of claim 12, wherein the superoxide dismutase mimetic is administered as a pharmaceutical composition comprising the superoxide dismutase mimetic corresponding to Formula (GC4419) and a pharmaceutically acceptable carrier.

### Claim at position 21 (depends on 1, 12)

21: The method of claim 12, wherein the superoxide dismutase mimetic is administered in the form of the unit dose formulation of claim 1.

### Claim at position 22 (depends on 12)

22: The method of claim 12, wherein the superoxide dismutase mimetic is dissolved in a solution comprising about 0.25 mg/mL to about 3.5 mg/mL superoxide dismutase mimetic and contained in an IV bag.

### Claim at position 23 (depends on 12)

23: The method of claim 12, wherein X and Y are independently selected from monodentate ligands.

### Claim at position 24 (depends on 12)

24: The method of claim 12, wherein X and Y are independently selected from the group consisting of aquo ligands, halo ligands, carboxylato ligands, and bicarbonato ligands.

### Claim at position 25 (depends on 24)

25: The method of claim 24, wherein X and Y are chloro ligands.

### Claim at position 26

26: A method of treating a disease or condition in a human patient, the method comprising administering to the patient a superoxide dismutase mimetic to provide an exposure as measured by an area under the curve (AUC) of at least 4,000 ng-h/mL as calculated from the measurement of the superoxide dismutase mimetic concentration in the patient's plasma, wherein the superoxide dismutase mimetic corresponds to Formula (GC4419):
and X and Y are independently neutral or negatively-charged ligands.

### Claim at position 27 (depends on 26)

27: The method of claim 26, wherein the administration provides an exposure as measured by an area under the curve (AUC) of at least 50,000 ng-h/mL as calculated from the measurement of the superoxide dismutase mimetic concentration in the patient's plasma.

### Claim at position 28 (depends on 26)

28: The method of claim 26, wherein the superoxide dismutase mimetic is administered parenterally.

### Claim at position 29 (depends on 26)

29: The method of claim 26, wherein the superoxide dismutase mimetic is administered intravenously.

### Claim at position 30 (depends on 26)

30: The method of claim 26, wherein the superoxide dismutase mimetic is administered as a pharmaceutical composition comprising the superoxide dismutase mimetic corresponding to Formula (GC4419) and a pharmaceutically acceptable carrier.

### Claim at position 31 (depends on 1, 26)

31: The method of claim 26, wherein the superoxide dismutase mimetic is administered in the form of the unit dose formulation of claim 1.

### Claim at position 32 (depends on 26)

32: The method of claim 26, wherein the superoxide dismutase mimetic is dissolved in a solution comprising about 0.25 mg/mL to about 3.5 mg/mL superoxide dismutase mimetic and contained in an IV bag.

### Claim at position 33 (depends on 26)

33: The method of claim 26, wherein X and Y are independently selected from monodentate ligands.

### Claim at position 34 (depends on 26)

34: The method of claim 26, wherein X and Y are independently selected from the group consisting of aquo ligands, halo ligands, carboxylato ligands, and bicarbonato ligands.

### Claim at position 35 (depends on 34)

35: The method of claim 34, wherein X and Y are chloro ligands.

### Claim at position 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

36: An article of manufacture, comprising packaging material and contained within said packaging material a parenteral formulation for treating a disease or condition or for protecting tissue against damage resulting from exposure to a cancer treatment in a patient in need thereof, wherein said parenteral formulation comprises a unit dose formulation of any of claims 1-20 and wherein said packaging material comprises a label or package insert with instructions for parenterally administering the dose to the patient.

### Claim at position 37 (depends on 36)

37: The article of manufacture of claim 36, wherein the parenteral formulation is in solution form, comprising about 20 mg/mL superoxide dismutase mimetic, the formulation being a unit dose in a container.

### Claim at position 38 (depends on 36)

38: The article of manufacture of claim 36, wherein the parenteral formulation is in solution form, comprising about 5 mg/mL superoxide dismutase mimetic, the formulation being a unit dose in a container.

### Claim at position 39 (depends on 36)

39: The method of claim 36, wherein X and Y are independently selected from monodentate ligands.

### Claim at position 40 (depends on 36)

40: The method of claim 36, wherein X and Y are independently selected from the group consisting of aquo ligands, halo ligands, carboxylato ligands, and bicarbonato ligands.

### Claim at position 41 (depends on 40)

41: The method of claim 40, wherein X and Y are chloro ligands.
